Evidence of resistance to type I inhibitors in model systems of B‐ALL is already driving the development of type II JAK inhibitors.48 Targeting of mulitple pathways was an approach taken by Suryani et al, (2015) in assessing the JAK inhibitor, AZD1480, alone and in combination with the MEK inhibitor, Selumetinib.49 While this study showed a strong anti‐leukaemic effect in vitro, only modest effects were seen in vivo, an important consideration for future preclinical testing, which highlights the need to identify other common targets to provide further options for more patients. Here, MAP2K7 is linked to acute lymphoblastic leukemia.